BridgeBio Pharma, Inc.
DE ˙ MUN ˙ US10806X1028
€ 56,19 ↓ -1.02 (-1.78%)
2026-06-01
PREÇO DA AÇÃO
SecurityDE:2CL / BridgeBio Pharma, Inc.
InstitutionMorgan Stanley
Latest Disclosed Ownership1,877,359 shares
Latest Disclosed Value $ 139,412,745
Morgan Stanley reports 34.12% increase in ownership of 2CL / BridgeBio Pharma, Inc.

On May 15, 2026 - Morgan Stanley filed a 13F-HR form disclosing ownership of 1,877,359 shares of BridgeBio Pharma, Inc. (DE:2CL) valued at $117,973,240 USD as of March 31, 2026. The entity filed a previous 13F-HR/A on May 27, 2026 disclosing 1,399,809 shares of BridgeBio Pharma, Inc.. This represents a change in shares of 34.12% during the quarter. The current value of the position is $105,488,802 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F BRIDGEBIO PHARMA COM 10806X102 1,877,359 477,550 34.12 139,413 30.21 0.0084
2026-05-27 2025-12-31 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 1,399,809 344,944 32.70 107,071 95.42 0.0064
2026-02-13 2025-12-31 13F BRIDGEBIO PHARMA COM 10806X102 1,399,809 344,944 107,071 0.0064
2026-05-27 2025-09-30 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 1,054,865 -287,513 -21.42 54,790 -5.48 0.0033
2025-11-14 2025-09-30 13F BRIDGEBIO PHARMA COM 10806X102 1,054,865 -287,513 54,790 0.0033
2025-08-15 2025-06-30 13F BRIDGEBIO PHARMA COM 10806X102 1,342,378 -156,241 -10.43 57,964 11.88 0.0038
2025-05-15 2025-03-31 13F BRIDGEBIO PHARMA COM 10806X102 1,498,619 247,002 19.73 51,807 50.85 0.0037
2025-05-15 2024-12-31 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 1,251,617 -124,125 -9.02 34,344 -1.95 0.0024
2025-02-14 2024-12-31 13F BRIDGEBIO PHARMA COM 10806X102 1,251,617 -124,125 34,344 0.0024
2025-05-14 2024-09-30 13F/A-2 BRIDGEBIO PHARMA COM 10806X102 1,375,742 -53,267 -3.73 35,026 -3.23 0.0025
2025-02-14 2024-09-30 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 1,375,742 -53,267 35,026 0.0025
2024-11-14 2024-09-30 13F BRIDGEBIO PHARMA COM 10806X102 1,375,742 -53,267 35,026 0.0003
2025-05-14 2024-06-30 13F/A-2 BRIDGEBIO PHARMA COM 10806X102 1,429,009 247,115 20.91 36,197 -0.95 0.0028
2024-10-17 2024-06-30 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 1,429,009 247,115 36,197 0.0028
2024-08-14 2024-06-30 13F BRIDGEBIO PHARMA COM 10806X102 1,429,009 247,115 36,197 0.0028
2024-10-17 2024-03-31 13F/A-2 BRIDGEBIO PHARMA COM 10806X102 1,181,894 -477,888 -28.79 36,544 -45.46 0.0029
2024-08-16 2024-03-31 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 1,181,894 -477,888 36,544 0.0029
2024-05-15 2024-03-31 13F BRIDGEBIO PHARMA COM 10806X102 1,181,894 -477,888 36,544 0.0029
2024-08-16 2023-12-31 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 1,659,782 211,722 14.62 67,005 75.47 0.0059
2024-02-13 2023-12-31 13F BRIDGEBIO PHARMA COM 10806X102 1,659,782 211,722 67,005 0.0059
2023-11-15 2023-09-30 13F BRIDGEBIO PHARMA COM 10806X102 1,448,060 894,647 161.66 38,185 301.19 0.0039
2023-08-14 2023-06-30 13F BRIDGEBIO PHARMA COM 10806X102 553,413 -361,378 -39.50 9,519 -37.25 0.0009
2023-05-15 2023-03-31 13F BRIDGEBIO PHARMA COM 10806X102 914,791 -141,046 -13.36 15,167 88.53 0.0016
2023-02-14 2022-12-31 13F BRIDGEBIO PHARMA COM 10806X102 1,055,837 32,023 3.13 8,045 -20.94 0.0009
2022-11-14 2022-09-30 13F BRIDGEBIO PHARMA COM 10806X102 1,023,814 -310,646 -23.28 10,176 -16.03 0.0014
2022-10-27 2022-06-30 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 1,334,460 177,522 15.34 12,118 3.19 0.0016
2022-08-15 2022-06-30 13F BRIDGEBIO PHARMA COM 10806X102 1,334,460 177,522 12,118 0.0016
2022-10-27 2022-03-31 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 1,156,938 762,451 193.28 11,743 78.49 0.0016
2022-05-13 2022-03-31 13F BRIDGEBIO PHARMA COM 10806X102 1,156,938 762,451 11,743 0.0016
2022-02-14 2021-12-31 13F BRIDGEBIO PHARMA COM 10806X102 394,487 174,978 79.71 6,579 -36.05 0.0008
2021-11-15 2021-09-30 13F BRIDGEBIO PHARMA COM 10806X102 219,509 -167,909 -43.34 10,288 -56.44 0.0014
2021-08-23 2021-06-30 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 387,418 -56,084 -12.65 23,616 -13.56 0.0031
2021-08-16 2021-06-30 13F BRIDGEBIO PHARMA COM 10806X102 387,418 -56,084 23,616 0.0006
2021-05-17 2021-03-31 13F BRIDGEBIO PHARMA COM 10806X102 443,502 369,317 497.83 27,320 417.91 0.0040
2021-02-16 2020-12-31 13F BRIDGEBIO PHARMA COM 10806X102 74,185 50,494 213.14 5,275 493.36 0.0008
2020-11-13 2020-09-30 13F BRIDGEBIO PHARMA COM 10806X102 23,691 -35,826 -60.19 889 -54.20 0.0002
2020-08-14 2020-06-30 13F BRIDGEBIO PHARMA COM 10806X102 59,517 37,102 165.52 1,941 198.62 0.0004
2020-05-26 2020-03-31 13F/A-1 BRIDGEBIO PHARMA COM 10806X102 22,415 -15,855 -41.43 650 -51.56 0.0002
2020-05-15 2020-03-31 13F BRIDGEBIO PHARMA COM 10806X102 22,415 -15,855 650 49.9336
2020-02-14 2019-12-31 13F BRIDGEBIO PHARMA COM 10806X102 38,270 29,682 345.62 1,342 625.41 0.0003
2019-11-14 2019-09-30 13F BRIDGEBIO PHARMA COM 10806X102 8,588 -21,112 -71.08 185 -76.90 0.0000
2019-08-14 2019-06-30 13F BRIDGEBIO PHARMA COM 10806X102 29,700 29,700 801 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.